Pay-Per-Lead Campaigns for Fitness & Wellness

42% of U.S. Adults Are Obese — and Every One of Them Calls Asking About Ozempic vs. Compounded Semaglutide

With 111 million adult Americans affected by obesity and GLP-1 prescription volumes up 300% between 2020 and 2022, your front desk is fielding a wave of inquiries from patients confused about branded GLP-1 receptor agonists like Wegovy and Ozempic versus compounded semaglutide. Each unqualified call consumes 10–15 minutes of staff time explaining medication options, dosing, and realistic timelines — the 15% body weight loss seen in semaglutide clinical trials sets expectations your team has to manage call after call, before a single new patient is ever booked.

Insurance Verification Is Eating Your Intake Capacity in a Market Headed Toward $100 Billion

GLP-1 coverage is notoriously inconsistent — benefits vary plan by plan, forcing your staff into repeated phone calls with insurers just to confirm whether semaglutide is covered. With over 40% of inquiry volume tied to coverage questions and the GLP-1 market projected to exceed $100 billion by 2030, every hour spent on hold with an insurance company is an hour not spent converting the surge of eligible patients — especially when only 1–2% of eligible patients are currently being prescribed obesity medication, leaving enormous untapped demand.

Dosage-Titration Follow-Up Calls Are Crowding Out New Patient Intake

GLP-1 protocols require gradual dose escalation, and patients uncertain about titration schedules or weight loss timelines call constantly for reassurance. These high-frequency follow-up calls tie up clinical staff, delay responses to new inquiries, and shrink your capacity to onboard new semaglutide patients — a critical problem in a market where of prospective patients choose the first clinic that responds.

Reduce Time Spent on Insurance and Medication Confusion Calls

Every GLP-1 lead you receive is pre-qualified through AI voice, SMS, and email follow-up before it reaches your front desk — so your staff spends less time explaining branded vs. compounded semaglutide and verifying insurance, and more time treating patients. Leads arrive with consent records attached, delivered straight into your CRM.

Over 40% of U.S. adults have obesity, creating sustained high inquiry volume for weight management clinics.

Increase Speed-to-Lead and Improve Contact Rates

AI follow-up contacts every lead within five minutes — 24/7 — via voice, SMS, and email. Contacting a lead within five minutes makes contact roughly 100x more likely than at thirty minutes, and with of buyers choosing whoever responds first, speed-to-lead is the difference between booking the semaglutide consult and losing them to the clinic down the street.

The GLP-1 market is projected to exceed $100 billion by 2030 — demand is accelerating, and first responders win it.

Access a Steady Stream of Exclusive, Non-Shared GLP-1 Leads

Choose exclusive leads (yours alone) or capped-shared leads delivered to a hard maximum of two buyers — never five, unlike shared marketplaces. With only 1–2% of eligible patients currently prescribed obesity medication, the pool of serious GLP-1 inquiries is too valuable to compete for five-ways.

Only 1–2% of eligible patients in the USA are currently prescribed medication or offered surgery for obesity treatment — qualified demand vastly outstrips supply.

Tell Us Your Niche and Goal

Specify that you need exclusive GLP-1 or semaglutide leads for your medical weight loss clinic, or request reactivation of your existing opted-in patient list.

We Source and Qualify Leads with AI Follow-Up

We deliver fresh, consent-recorded leads or reactivate your dormant list using multi-channel AI (SMS first, then voice, then email), DNC-scrubbed and qualified before CRM delivery.

Leads Land in Your CRM — Ready to Book

Each lead arrives with its consent trail attached, having already been contacted by AI within five minutes — so your team only engages with warm, verified prospects.